Corbus Pharma (CRBP) |
|
1.88 -0.34 (-15.32%)
|
03-05 08:22 |
|
Open: |
2.15 |
Pre. Close: |
2.22 |
|
High:
|
2.245 |
Low:
|
1.7701 |
|
Volume:
|
16,319,423 |
Market Cap:
|
158M |
|
|
|
|
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.242 - 2.261 |
2.261 - 2.273 |
|
Low:
|
1.739 - 1.756 |
1.756 - 1.767 |
|
Close:
|
1.857 - 1.884 |
1.884 - 1.902 |
|
Technical analysis |
as of: 2021-03-05 8:08:58 AM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 3.67 One year: 4.67 |
| Support: |
Support1: 1.75 Support2: 1.46 |
| Resistance: |
Resistance1: 3.14 Resistance2: 4.00 |
| Pivot: |
2.61 |
| Moving Average: |
MA(5): 2.20 MA(20): 2.69
MA(100): 1.64  MA(250): 4.25 |
| MACD: |
MACD(12,26): -0.01 Signal(9): 0.12 |
| Stochastic oscillator: |
%K(14,3): 9.93 %D(3): 12.79 |
| RSI: |
RSI(14): 37.11 |
| 52-week: |
High: 9.78 Low: 0.91 Change(%): -58.5 |
| Average Vol(K): |
3-Month: 1551885 10-Days: 1186296 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.CRBP has closed above bottom band by 2.8%. Bollinger Bands are 104% wider than normal. The large width of the bands suggest high volatility as compared to CRBP's normal range. The bands have been in this wide range for 6 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 04 Mar 2021
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Yahoo Finance
Mon, 01 Mar 2021
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Sat, 27 Feb 2021
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Expected to Post Quarterly Sales of $1.24 Million - MarketBeat
Fri, 26 Feb 2021
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Wed, 17 Feb 2021
Corbus Pharmaceuticals Holdings Inc. stock falls Wednesday, underperforms market - MarketWatch
Tue, 16 Feb 2021
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, outperforms market - MarketWatch
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
84 |
| Shares Float (M) |
77 |
|
% Held by Insiders
|
1.73 |
|
% Held by Institutions
|
75.49 |
|
Shares Short (K)
|
16,250 |
|
Shares Short P. Month (K)
|
31,660 |
Stock Financials |
|
EPS
|
-1.784 |
|
EPS Est This Year
|
-0.640 |
|
EPS Est Next Year
|
-0.680 |
|
Book Value (p.s.)
|
0.360 |
|
Profit Margin
|
|
|
Operating Margin
|
-2207.39 |
|
Return on Assets (ttm)
|
-98.5 |
|
Return on Equity (ttm)
|
-439.1 |
|
Qtrly Rev. Growth
|
-52.5 |
|
Gross Profit (p.s.)
|
-0.636 |
|
Sales Per Share
|
0.070 |
|
EBITDA (p.s.)
|
-1.524 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-104 |
|
Levered Free Cash Flow (M)
|
-58 |
Stock Valuations |
|
PE Ratio
|
-1.05 |
|
PEG Ratio
|
|
|
Price to Book value
|
5.22 |
|
Price to Sales
|
27.01 |
|
Price to Cash Flow
|
-1.52 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
